Total assets                          $  6,740,140   $ 12,212,609 
                                       ===========    =========== 
LIABILITIES AND STOCKHOLDERS' 
EQUITY 
Current liabilities: 
   Accounts payable                   $  3,127,348   $  1,359,898 
   Accrued expenses                        934,372      1,152,460 
   Deferred underwriting commissions            --      2,911,260 
   Warrant liability                         4,803        141,276 
                                       -----------    ----------- 
      Total current liabilities          4,066,523      5,564,894 
                                       -----------    ----------- 
Total liabilities                        4,066,523      5,564,894 
                                       -----------    ----------- 
 
Stockholders' equity: 
   Common Stock, $0.001 par value; 
    500,000,000 shares authorized at 
    September 30, 2024 and December 
    31, 2023 and 4,292,455 and 
    264,537 issued and outstanding 
    at September 30, 2024 and 
    December 31, 2023, respectively          4,292            265 
   Additional paid-in-capital           41,449,244     32,114,552 
   Accumulated deficit                 (38,779,919)   (25,467,102) 
                                       -----------    ----------- 
      Total stockholders' equity         2,673,617      6,647,715 
                                       -----------    ----------- 
Total liabilities and stockholders' 
 equity                               $  6,740,140   $ 12,212,609 
                                       ===========    =========== 
 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241108038521/en/

 
    CONTACT:    Chester Zygmont, III 

Chief Financial Officer

Revelation Biosciences, Inc.

Email: czygmont@revbiosciences.com

(END) Dow Jones Newswires

November 08, 2024 16:15 ET (21:15 GMT)